HC Wainwright Reaffirms Buy Rating for ReWalk Robotics (NASDAQ:LFWD)

HC Wainwright reaffirmed their buy rating on shares of ReWalk Robotics (NASDAQ:LFWD) in a report released on Thursday,Benzinga reports. The firm currently has a $13.00 target price on the stock.

Separately, Laidlaw initiated coverage on shares of ReWalk Robotics in a research note on Monday, February 10th. They issued a “buy” rating and a $10.00 price objective for the company.

ReWalk Robotics Stock Performance

NASDAQ LFWD opened at $1.84 on Thursday. ReWalk Robotics has a 12-month low of $1.25 and a 12-month high of $7.70. The company has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $2.42.

Insider Activity at ReWalk Robotics

In related news, Director Michael Swinford purchased 21,622 shares of the stock in a transaction on Monday, November 25th. The shares were bought at an average price of $2.03 per share, for a total transaction of $43,892.66. Following the completion of the acquisition, the director now directly owns 65,040 shares in the company, valued at approximately $132,031.20. This trade represents a 49.80 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Global Fund Lp Lind II sold 381,676 shares of ReWalk Robotics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $3.36, for a total transaction of $1,282,431.36. Following the completion of the transaction, the insider now directly owns 1,049,430 shares in the company, valued at approximately $3,526,084.80. This represents a 26.67 % decrease in their position. The disclosure for this sale can be found here. 2.50% of the stock is owned by company insiders.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.